KRW 6600.0
(-5.44%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 707.09 Billion KRW | 1.97% |
2022 | 693.45 Billion KRW | -5.96% |
2021 | 737.42 Billion KRW | 49.34% |
2020 | 493.78 Billion KRW | 1.91% |
2019 | 484.53 Billion KRW | 382.01% |
2018 | 100.52 Billion KRW | 0.32% |
2017 | 100.2 Billion KRW | 3.04% |
2016 | 97.24 Billion KRW | -72.66% |
2015 | 355.65 Billion KRW | 23.75% |
2014 | 287.39 Billion KRW | -4.71% |
2013 | 301.6 Billion KRW | 38.8% |
2012 | 217.29 Billion KRW | 7.85% |
2011 | 201.48 Billion KRW | -14.71% |
2010 | 236.23 Billion KRW | 9.74% |
2009 | 215.26 Billion KRW | 8.76% |
2008 | 197.92 Billion KRW | 41.1% |
2007 | 140.27 Billion KRW | 26.62% |
2006 | 110.78 Billion KRW | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 695.49 Billion KRW | -1.64% |
2024 Q2 | 691.61 Billion KRW | -0.56% |
2023 Q4 | 707.09 Billion KRW | 3.13% |
2023 Q1 | 694.56 Billion KRW | 0.16% |
2023 Q2 | 708.54 Billion KRW | 2.01% |
2023 FY | 707.09 Billion KRW | 1.97% |
2023 Q3 | 685.62 Billion KRW | -3.23% |
2022 Q3 | 665.98 Billion KRW | 0.38% |
2022 Q1 | 698.9 Billion KRW | -5.22% |
2022 FY | 693.45 Billion KRW | -5.96% |
2022 Q4 | 693.45 Billion KRW | 4.13% |
2022 Q2 | 663.47 Billion KRW | -5.07% |
2021 Q1 | 598.92 Billion KRW | 21.29% |
2021 FY | 737.42 Billion KRW | 49.34% |
2021 Q4 | 737.42 Billion KRW | 15.96% |
2021 Q3 | 635.95 Billion KRW | 3.61% |
2021 Q2 | 613.79 Billion KRW | 2.48% |
2020 Q2 | 471.24 Billion KRW | -3.45% |
2020 Q1 | 488.05 Billion KRW | 0.73% |
2020 FY | 493.78 Billion KRW | 1.91% |
2020 Q3 | 470.08 Billion KRW | -0.25% |
2020 Q4 | 493.78 Billion KRW | 5.04% |
2019 FY | 484.53 Billion KRW | 382.01% |
2019 Q4 | 484.53 Billion KRW | 2.17% |
2019 Q2 | 110.94 Billion KRW | 0.59% |
2019 Q1 | 110.29 Billion KRW | 9.72% |
2019 Q3 | 474.25 Billion KRW | 327.48% |
2018 Q2 | 103.99 Billion KRW | -0.4% |
2018 Q1 | 104.41 Billion KRW | 4.2% |
2018 FY | 100.52 Billion KRW | 0.32% |
2018 Q4 | 100.52 Billion KRW | -4.5% |
2018 Q3 | 105.25 Billion KRW | 1.22% |
2017 Q4 | 100.2 Billion KRW | 0.31% |
2017 FY | 100.2 Billion KRW | 3.04% |
2017 Q1 | 81.53 Billion KRW | -16.16% |
2017 Q2 | 99.22 Billion KRW | 21.7% |
2017 Q3 | 99.89 Billion KRW | 0.67% |
2016 Q1 | 365.64 Billion KRW | 2.81% |
2016 Q4 | 97.24 Billion KRW | -1.53% |
2016 Q3 | 98.76 Billion KRW | -88.77% |
2016 Q2 | 879.72 Billion KRW | 140.59% |
2016 FY | 97.24 Billion KRW | -72.66% |
2015 Q4 | 355.65 Billion KRW | 19.46% |
2015 FY | 355.65 Billion KRW | 23.75% |
2015 Q3 | 297.71 Billion KRW | 2.19% |
2015 Q2 | 291.34 Billion KRW | 1.83% |
2015 Q1 | 286.1 Billion KRW | -0.45% |
2014 FY | 287.39 Billion KRW | -4.71% |
2014 Q4 | 287.39 Billion KRW | 1.01% |
2014 Q3 | 284.52 Billion KRW | 1.21% |
2014 Q2 | 281.12 Billion KRW | 1.82% |
2014 Q1 | 276.1 Billion KRW | -8.45% |
2013 Q4 | 301.6 Billion KRW | 3.88% |
2013 FY | 301.6 Billion KRW | 38.8% |
2013 Q3 | 290.33 Billion KRW | -3.33% |
2013 Q1 | 231.76 Billion KRW | 6.66% |
2013 Q2 | 300.34 Billion KRW | 29.59% |
2012 FY | 217.29 Billion KRW | 7.85% |
2012 Q4 | 217.29 Billion KRW | 0.0% |
2012 Q1 | 183.94 Billion KRW | 0.0% |
2011 Q1 | 186.56 Billion KRW | 0.0% |
2011 Q2 | 184.77 Billion KRW | -0.96% |
2011 Q3 | 186.72 Billion KRW | 1.05% |
2011 FY | 201.48 Billion KRW | -14.71% |
2010 Q2 | 175.93 Billion KRW | 0.0% |
2010 Q3 | 163.67 Billion KRW | -6.97% |
2010 FY | 236.23 Billion KRW | 9.74% |
2009 Q4 | 171 Billion KRW | 5.79% |
2009 Q3 | 161.65 Billion KRW | 10.81% |
2009 FY | 215.26 Billion KRW | 8.76% |
2009 Q2 | 145.88 Billion KRW | 0.0% |
2008 Q4 | 122.48 Billion KRW | 5.19% |
2008 Q2 | 109.04 Billion KRW | 0.0% |
2008 Q3 | 116.43 Billion KRW | 6.78% |
2008 FY | 197.92 Billion KRW | 41.1% |
2007 FY | 140.27 Billion KRW | 26.62% |
2007 Q2 | 94.24 Billion KRW | 0.0% |
2007 Q4 | 100.23 Billion KRW | 8.43% |
2007 Q3 | 92.44 Billion KRW | -1.9% |
2006 FY | 110.78 Billion KRW | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Yuyu Pharma, Inc. | 77.85 Billion KRW | -808.19% |
Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 23.951% |
HANDOK Inc. | 449.7 Billion KRW | -57.235% |
Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -725.37% |
Yuhan Corporation | 712.33 Billion KRW | 0.736% |
Dong-A ST Co., Ltd. | 631.91 Billion KRW | -11.898% |
SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -4348.695% |
Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 16.99% |
Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -1220.97% |
Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -243.459% |
Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -840.652% |
MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -378.433% |
Hana Pharm Co., Ltd. | 70.4 Billion KRW | -904.381% |
Yuyu Pharma, Inc. | 77.85 Billion KRW | -808.19% |
Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -1840.642% |
REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -181.543% |
Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -220.381% |
JW Holdings Corporation | 827.51 Billion KRW | 14.551% |
Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | -61.809% |
Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | -20.502% |
JW Pharmaceutical Corporation | 379.59 Billion KRW | -86.275% |
Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -791.657% |
Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -910.606% |
Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -191.163% |
Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | -114.081% |
Yuyu Pharma, Inc. | 77.85 Billion KRW | -808.19% |
Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | -44.3% |
Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 17.591% |
JW Pharmaceutical Corporation | 379.59 Billion KRW | -86.275% |
Yuhan Corporation | 712.33 Billion KRW | 0.736% |
Jeil Pharma Holdings Inc | 477.81 Billion KRW | -47.987% |
Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -416.248% |
Suheung Co., Ltd. | 516.66 Billion KRW | -36.857% |
JW Pharmaceutical Corporation | 379.59 Billion KRW | -86.275% |
Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -357.561% |
Korea United Pharm Inc. | 89.96 Billion KRW | -685.966% |
CKD Bio Corp. | 170.76 Billion KRW | -314.087% |
Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -190.11% |
Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -348.504% |
Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -1543.68% |
Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -791.657% |
Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | -11.791% |
Boryung Corporation | 373.1 Billion KRW | -89.515% |
Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -239.628% |
Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -243.459% |
JW Lifescience Corporation | 96.44 Billion KRW | -633.174% |